Douglas S Swords1, Sean J Mulvihill2, Benjamin S Brooke2, David E Skarda3, Matthew A Firpo2, Courtney L Scaife2. 1. Department of Surgery, University of Utah, Salt Lake City; Surgical Services Clinical Program, Intermountain Healthcare, Salt Lake City, UT. Electronic address: douglas.swords@hsc.utah.edu. 2. Department of Surgery, University of Utah, Salt Lake City. 3. Department of Surgery, University of Utah, Salt Lake City; Surgical Services Clinical Program, Intermountain Healthcare, Salt Lake City, UT.
Abstract
BACKGROUND: Utilization of multimodality therapy for clinical stage I-II pancreatic ductal adenocarcinoma is associated with meaningful prolongation of survival. Although the qualitative existence of disparities in treatment utilization by socioeconomic status and race/ethnicity is well documented, the absolute magnitudes of these disparities have not been previously quantified. METHODS: The exposures in this retrospective cohort study of the 2010-2015 National Cancer Database were a 7-value area-level socioeconomic status index and race/ethnicity. Main outcomes were surgery, chemotherapy, and multimodality therapy (surgery and chemotherapy). Adjusted rate differences were calculated after logistic regression. Models excluded intermediate variables. Overall survival was evaluated in unadjusted and adjusted analyses. RESULTS: Of 43,760 patients, 63.4% underwent surgery. Of 39,808 patients without chemotherapy contraindications, refusal, or missing data, 75.1% received chemotherapy and 51.4% received multimodality therapy. Adjusted rate differences for utilization of surgery, chemotherapy, and multimodality therapy in the lowest socioeconomic status patients were -10.0 (95% confidence interval [CI] -12.4 to -7.5), -12.7 (95% CI -16.3 to -9.1), and -15.4 (95% CI -18.8 to -12.0), respectively, versus the highest socioeconomic status patients. Adjusted rate differences for multimodality therapy utilization in non-Hispanic Black and Hispanic patients were -10.1 (95% CI -13.6 to -6.7) and -11.8 (95% CI -14.3 to -9.2), respectively, versus non-Hispanic White patients. Median overall survival increased in a graded fashion from 14.1 (95% CI 13.4-14.8) months in the lowest socioeconomic status patients to 20.2 months (95% CI 19.6-20.8) in the highest socioeconomic status patients. Survival differences were attenuated but not eliminated in multivariable Cox models. CONCLUSION: Socioeconomic status and race/ethnicity are more powerful determinants of whether patients receive treatment for clinical stage I-II pancreatic ductal adenocarcinoma than previously appreciated. Nationwide quality improvement efforts aimed at addressing these inequities are warranted.
BACKGROUND: Utilization of multimodality therapy for clinical stage I-II pancreatic ductal adenocarcinoma is associated with meaningful prolongation of survival. Although the qualitative existence of disparities in treatment utilization by socioeconomic status and race/ethnicity is well documented, the absolute magnitudes of these disparities have not been previously quantified. METHODS: The exposures in this retrospective cohort study of the 2010-2015 National Cancer Database were a 7-value area-level socioeconomic status index and race/ethnicity. Main outcomes were surgery, chemotherapy, and multimodality therapy (surgery and chemotherapy). Adjusted rate differences were calculated after logistic regression. Models excluded intermediate variables. Overall survival was evaluated in unadjusted and adjusted analyses. RESULTS: Of 43,760 patients, 63.4% underwent surgery. Of 39,808 patients without chemotherapy contraindications, refusal, or missing data, 75.1% received chemotherapy and 51.4% received multimodality therapy. Adjusted rate differences for utilization of surgery, chemotherapy, and multimodality therapy in the lowest socioeconomic status patients were -10.0 (95% confidence interval [CI] -12.4 to -7.5), -12.7 (95% CI -16.3 to -9.1), and -15.4 (95% CI -18.8 to -12.0), respectively, versus the highest socioeconomic status patients. Adjusted rate differences for multimodality therapy utilization in non-Hispanic Black and Hispanic patients were -10.1 (95% CI -13.6 to -6.7) and -11.8 (95% CI -14.3 to -9.2), respectively, versus non-Hispanic White patients. Median overall survival increased in a graded fashion from 14.1 (95% CI 13.4-14.8) months in the lowest socioeconomic status patients to 20.2 months (95% CI 19.6-20.8) in the highest socioeconomic status patients. Survival differences were attenuated but not eliminated in multivariable Cox models. CONCLUSION: Socioeconomic status and race/ethnicity are more powerful determinants of whether patients receive treatment for clinical stage I-II pancreatic ductal adenocarcinoma than previously appreciated. Nationwide quality improvement efforts aimed at addressing these inequities are warranted.
Authors: Ryan J Ellis; Cary Jo R Schlick; Joe Feinglass; Mary F Mulcahy; Al B Benson; Sheetal M Kircher; Tony D Yang; David D Odell; Karl Bilimoria; Ryan P Merkow Journal: BMJ Qual Saf Date: 2019-07-31 Impact factor: 7.035
Authors: Rittal Mehta; Kota Sahara; Katiuscha Merath; J Madison Hyer; Diamantis I Tsilimigras; Anghela Z Paredes; Aslam Ejaz; Jordan M Cloyd; Mary Dillhoff; Allan Tsung; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2019-06-13 Impact factor: 3.452
Authors: Nadia N Khan; Tennille Lewin; Amy Hatton; Charles Pilgrim; Liane Ioannou; Luc Te Marvelde; John Zalcberg; Sue Evans Journal: Am J Cancer Res Date: 2022-02-15 Impact factor: 6.166
Authors: Douglas S Swords; Brian K Bednarski; Craig A Messick; Matthew M Tillman; George J Chang; Y Nancy You Journal: Ann Surg Oncol Date: 2021-08-18 Impact factor: 5.344
Authors: Andrea M Schiefelbein; John K Krebsbach; Amy K Taylor; Jienian Zhang; Chloe E Haimson; Amy Trentham-Dietz; Melissa C Skala; John M Eason; Sharon M Weber; Patrick R Varley; Syed N Zafar; Noelle K LoConte Journal: WMJ Date: 2022-07
Authors: Patrick W Underwood; Andrea N Riner; Dan Neal; Miles E Cameron; Anastasiya Yakovenko; Sushanth Reddy; John Bart Rose; Steven J Hughes; Jose G Trevino Journal: J Surg Oncol Date: 2021-09-09 Impact factor: 2.885
Authors: Annabelle L Fonseca; Hamza Khan; Krista R Mehari; Deepa Cherla; Martin J Heslin; Fabian M Johnston Journal: Ann Surg Oncol Date: 2022-01-23 Impact factor: 5.344